Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
Harry L.A. Janssen(Erasmus MC), Robert J. de Knegt(Erasmus MC), Vincenza Calvaruso(University of Palermo), Raoel Maan(Erasmus MC), Ola Weiland(Karolinska University Hospital), Bettina E. Hansen(Aarhus University), Conrado Fernández‐Rodríguez(Universidad Rey Juan Carlos), Soo Aleman(Karolinska University Hospital), V. Di Marco(University of Palermo), Jordan J. Feld(University Health Network), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ricardo Moreno‐Otero(Hospital Universitario de La Princesa), Piero Luigi Almasio(University of Palermo), Stanislas Pol(Université Paris Cité), Nathalie Ganne‐Carrié(Inserm), Sonia Alonso Sáenz De Oger(Hospital Universitario Fundación Alcorcón), Savino Bruno(Humanitas University), Harald Hofer(Klinikum Wels-Grieskirchen), Rolf Hultcrantz(Karolinska Institutet), María Trapero-Marugán(Hospital Universitario de La Princesa), Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Bart J. Veldt(Erasmus MC), Vincent Mallet(Université Paris Cité), Karoline Rutter(Universität Hamburg)
Cited by 273
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907